GENTAUR Belgium BVBA BE0473327336
Voortstraat 49, 1910 Kampenhout BELGIUM
Tel 0032 16 58 90 45
GENTAUR U.S.A Genprice Inc 6017 Snell Ave, Ste 357, SanJose, CA 95123
Tel (408) 780-0908, Fax (408) 780-0908, email@example.com
#1759-100 Gemcitabine Hydrochloride; Appearance White solid
Product name : Gemcitabine Hydrochloride; Appearance White solid
Catalog number : 1759-100
Quantity: 100 mg
Supplier name : Biovis
Data sheet: Ask more or other datasheet now !
More Details about
Alternate Name/Synonyms: 2′,2′-difluoro-2′-deoxycytidine; Gamcitabine; Gemcitera; Gemsar; Gemzar; LY-188011
Peptide sequence: N/A
Appearance: White solid
CAS Number: 122111-03-9
Molecular Formula: C₉H₁₁F₂N₃O₄•HCl
Molecular Weight: 299.66
Purity: ≥98% by HPLC
Solubility: DMSO (10 mg/ml) or H2O (25 mg/ml)
Storage Temp.: -20°C
Shipping Conditions: gel pack
Description: A nucleoside analog of deoxycytidine used in chemotherapy to treat various types of cancer. Gemcitabine is converted intracellularly to the active metabolites difluorodeoxycytidine di- and triphosphate (dFdCDP, dFdCTP). dFdCDP inhibits ribonucleotide reductase, thereby decreasing the deoxynucleotide pool available for DNA synthesis; dFdCTP is incorporated into DNA, resulting in DNA strand termination and apoptosis.
Handling: Protect from air and moisture
USAGE: For Research Use Only! Not For Use in Humans.
Contact us about this product :
Our team will respond you as soon as possible !
52062 Aachen Deutschland
Support Karolina Elandt
Fax: (+49) 241 56 00 47 88
Logistic :0241 40 08 90 86
IBAN lautet DE8839050000107569353
Handelsregister Aachen HR B 16058
Umsatzsteuer-Identifikationsnummer *** DE 815175831
firstname.lastname@example.org | Gentaur
Genprice Inc, Logistics
547, Yurok Circle
San Jose, CA 95123
Tel (408) 780-0908,
Fax (408) 780-0908,
Genprice Inc, Invoices and accounting
6017 Snell Ave, Ste 357
San Jose, CA 95123
Canada Montreal +15149077481
Ceská republika Praha +420246019719
Finland Helsset +358942419041
Magyarország Budapest +3619980547
US New York+17185132983
No related Items
Related Genes :
[ABCB1 MDR1 PGY1] Multidrug resistance protein 1 (EC 18.104.22.168) (ATP-binding cassette sub-family B member 1) (P-glycoprotein 1) (CD antigen CD243)
 Liver carboxylesterase (EC 22.214.171.124) (Proline-beta-naphthylamidase) (Retinyl ester hydrolase) (REH)
[TYMS TS OK/SW-cl.29] Thymidylate synthase (TS) (TSase) (EC 126.96.36.199)
[RNR1 CRT7 RIR1 SDS12 YER070W] Ribonucleoside-diphosphate reductase large chain 1 (EC 188.8.131.52) (Ribonucleotide reductase R1 subunit 1) (Ribonucleotide reductase large subunit 1)
[DCK] Deoxycytidine kinase (dCK) (EC 184.108.40.206)
[SLC28A3 CNT3] Solute carrier family 28 member 3 (Concentrative Na(+)-nucleoside cotransporter 3) (CNT 3) (hCNT3)
[CDA CDD] Cytidine deaminase (EC 220.127.116.11) (Cytidine aminohydrolase)
[SLC29A1 ENT1] Equilibrative nucleoside transporter 1 (Equilibrative nitrobenzylmercaptopurine riboside-sensitive nucleoside transporter) (Equilibrative NBMPR-sensitive nucleoside transporter) (Nucleoside transporter, es-type) (Solute carrier family 29 member 1)
[RRM1 RR1] Ribonucleoside-diphosphate reductase large subunit (EC 18.104.22.168) (Ribonucleoside-diphosphate reductase subunit M1) (Ribonucleotide reductase large subunit)
[CMPK1 CMK CMPK UCK UMK UMPK] UMP-CMP kinase (EC 22.214.171.124) (Deoxycytidylate kinase) (CK) (dCMP kinase) (Nucleoside-diphosphate kinase) (EC 126.96.36.199) (Uridine monophosphate/cytidine monophosphate kinase) (UMP/CMP kinase) (UMP/CMPK)
[RELB] Transcription factor RelB (I-Rel)
[SLC29A2 DER12 ENT2 HNP36] Equilibrative nucleoside transporter 2 (36 kDa nucleolar protein HNP36) (Delayed-early response protein 12) (Equilibrative nitrobenzylmercaptopurine riboside-insensitive nucleoside transporter) (Equilibrative NBMPR-insensitive nucleoside transporter) (Hydrophobic nucleolar protein, 36 kDa) (Nucleoside transporter, ei-type) (Solute carrier family 29 member 2)
[IER3 DIF2 IEX1 PRG1] Radiation-inducible immediate-early gene IEX-1 (Differentiation-dependent gene 2 protein) (Protein DIF-2) (Immediate early protein GLY96) (Immediate early response 3 protein) (PACAP-responsive gene 1 protein) (Protein PRG1)
[SLC28A1 CNT1] Sodium/nucleoside cotransporter 1 (Concentrative nucleoside transporter 1) (CNT 1) (hCNT1) (Na(+)/nucleoside cotransporter 1) (Sodium-coupled nucleoside transporter 1) (Solute carrier family 28 member 1)
[NUPR1 COM1] Nuclear protein 1 (Candidate of metastasis 1) (Nuclear transcriptional regulator protein 1) (Protein p8)
[ABCC10 MRP7 SIMRP7] Multidrug resistance-associated protein 7 (ATP-binding cassette sub-family C member 10)
[IER3 IEX1] Radiation-inducible immediate-early gene IEX-1 (Immediate early protein GLY96) (Immediate early response 3 protein)
 Genome polyprotein
[Slc28a3 Cnt3] Solute carrier family 28 member 3 (Concentrative Na(+)-nucleoside cotransporter 3) (CNT 3) (mCNT3)
[Slc28a3 Cnt3] Solute carrier family 28 member 3 (Concentrative Na(+)-nucleoside cotransporter 3) (CNT 3) (rCNT3)
[SLC28A3 CNT3] Solute carrier family 28 member 3 (Concentrative Na(+)-nucleoside cotransporter 3) (hfCNT)
 Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer.
 From Clinical Standards to Translating Next-Generation Sequencing Research into Patient Care Improvement for Hepatobiliary and Pancreatic Cancers.
 Therapeutic Potential of Curcumin in Treatment of Pancreatic Cancer: Current Status and Future Perspectives.
 Clinical and immunologic correlates of response to PD-1 blockade in a patient with metastatic renal medullary carcinoma.
 Annular rectal constriction caused by infiltrating bladder cancer: A case report.
 Activator protein 1 promotes gemcitabine-induced apoptosis in pancreatic cancer by upregulating its downstream target Bim.
 Locally advanced pancreatic cancer successfully treated by distal pancreatectomy with celiac axis resection (DP-CAR) after S-1 with radiation therapy followed by gemcitabine/nab-paclitaxel therapy: a case report.
 Histological complete response in a patient with advanced biliary tract cancer treated by gemcitabine/cisplatin/S-1 combination chemotherapy: A case report.
 A retrospective analysis of the clinical effects of neoadjuvant combination therapy with full-dose gemcitabine and radiation therapy in patients with biliary tract cancer.
 A gemcitabine based peptide conjugate with improved metabolic properties and dual mode of efficacy.
Enter catalog number :